Gutierrez NC, Hernandez JM, Garcia JL, Canizo MC, Gonzalez M, Hernandez J, et al. Differences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization. Leukemia 2001;15:840-5.
The current definition of plasma cell leukemia (PCL)— ≥ 20% circulating plasma cells (CPCs) on peripheral smear and plasma cell count ≥ 2 × 109/L—may be too stringent. We reviewed outcomes of 176 multiple myeloma (MM) patients diagnosed between 1971 and 2016, and who ha...
We describe a patient with multiple myeloma who was treated with intensive therapy and autologous blood cell transplantation as her first-line treatment. The disease relapsed 3 months after the transplant as plasma cell leukemia and the patient succumbed in 4 weeks. We suggest that an aggressive ...
Multiple Myeloma and Plasma Cell Dyscrasias Noopur Raje, ... Arthur T. Skarin, in Atlas of Diagnostic Oncology (Fourth Edition), 2010 Plasma Cell Leukemia PCL is characterized by the presence of more than 2 × 109 plasma cells per liter within the peripheral blood, which constitutes 20% o...
Plasma cell myeloma (PCM) of the skull base is rarely encountered in neurosurgical practice. PCM has a wide spectrum of pathology, including a quite benign, solitary plasmacytoma (SPC), and an extremely malignant, multiple myeloma (MM) at the two ends of the spectrum. We have described two ...
Primary plasma cell leukemia (pPCL) is a rare and aggressive plasma cell proliferative disorder with a very poor prognosis and with distinct biologic, clinical, and laboratory features. Compared with multiple myeloma, pPCL presents more often with extramedullary involvement, anemia, thrombocytopenia, hype...
Significance of Circulating Plasma Cells in Multiple Myeloma The number of circulating plasma cells (CPC) was determined on mononuclear cell preparations after Giemsa (morphology) and light chain staining (immunocyto... M Zandecki,T Facon,C Preudhomme,... - 《Leukemia & Lymphoma》 被引量: 20...
5b-f). The case was diagnosed as a post-transplant lymphoproliferative disorder with plasmacytic differentiation, compatible with plasma cell myeloma/plasma cell leukemia. Fig. 5 Bone marrow biopsy. (a) H&E, 4×, revealing two areas marked as 1 and 2 (b) H&E 20× from 1(c) H&E ...
Leukemia 2013; 27: 226–232. Article CAS PubMed Google Scholar Agirre X, Castellano G, Pascual M, Heath S, Kulis M, Segura V et al. Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers. Genome Res 2015; 25: 478–487. Article CAS Pub...
Using anti-CD38 immunotherapy to enhance anti-tumor T-cell immunity in chronic lymphocytic leukemia (CLL). J. Immunol. 200, 58.17 (2018). Google Scholar Pinto, D. et al. A functional BCR in human IgA and IgM plasma cells. Blood 121, 4110–4114 (2013). Article CAS PubMed Google ...